Sign up to our newsletter Subscribe
A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold

New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.